Vanguard Group’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Vanguard Group’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-3,533,008	Closed	-$32M	–	3975
2013 Q4	$32M	Buy	3,533,008 +149,802	+4%	+$1.08M	﹤0.01%	1991
2013 Q3	$21.3M	Buy	3,383,206 +137,036	+4%	+$871K	﹤0.01%	2080
2013 Q2	$22.1M	Buy	+3,246,170	New	+$22.6M	﹤0.01%	2041

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group's CADX Position: Q1 2014 in Review

Vanguard Group sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 3,533,008 shares — an estimated $32M sold.

Vanguard Group first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $32M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

Vanguard Group reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
Vanguard Group sold 3,533,008 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $32M.
Vanguard Group first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
Vanguard Group's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $32M in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Vanguard Group's 13F filing for Q1 2014, filed 13 May 2014.